



Achillion Pharmaceuticals  
 Investor Relations Department  
 300 George St.  
 New Haven, CT 06511  
 United States

Visit IR website [↗](#)  
 Sign-up for Email alerts [↗](#)

<b>NASDAQ: ACHN</b>	
Last Trade:	4.15
Trade Time:	4:00 PM ET Oct 20, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	3.15 - 7.10
Volume	2,212

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile


Rooted in the myth of Achilles, the name of Achillion refers to the brave warrior committed to a cause as well as the company's mission to combat diseases by identifying and exploiting their unique vulnerabilities.

### Inspiring Science. Innovative Medicine.

Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is a science-driven, patient-focused company leveraging its strengths across the continuum from drug discovery to commercialization to provide better treatments for people with serious diseases.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Oct 23, 2017*  
[Achillion Announces Presentation of Data From OMEGA-1 Phase 2b Trial With Odalasvir, AL-335, and Simeprevir \(JNJ-4178\) at the 2017 Liver Meeting](#)
- Sep 20, 2017*  
[Achillion to Present at the 2017 Leerink Partners Rare Disease Roundtable Series](#)
- Sep 11, 2017*  
[Achillion Announces Strengthening of Management Team](#)
- Sep 11, 2017*  
[Achillion Announces Termination of Worldwide Collaboration for Hepatitis C With Janssen](#)
- Aug 8, 2017*  
[Achillion Reports Second Quarter 2017 Financial Results and Proof-of-Concept With a First-in-Class, Oral Factor D Inhibitor](#)

## Financial Disclosures [\[ View all \]](#)

- [Second Quarter Financial Results](#)
- Feb 23, 2017*  
[Annual Report \(10-K\)](#)
- Apr 17, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Aug 8, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 4, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 3, 2016*  
[Quarterly Report \(10-Q\)](#)